Search results for "Static"

showing 10 items of 1528 documents

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

2008

Abstract Purpose: To determine the recommended dose, cardiac safety, and antitumor activity of nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and the anti-HER-2 monoclonal antibody trastuzumab in patients with HER-2-overexpressing locally advanced nonoperable breast cancer (LABC) and metastatic breast cancer (MBC). Experimental Design: Women with measurable, previously untreated, HER-2-overexpressing LABC and MBC with a baseline left ventricular ejection fraction (LVEF) >50% received weekly trastuzumab in combination with escalating doses of weekly paclitaxel and TLC-D99 every 3 weeks for 6 cycles. LVEF monitoring was done every 3 weeks for the first 18 weeks and every 8 w…

AdultCancer Researchmedicine.medical_specialtyHeart DiseasesPaclitaxelUrologyBreast NeoplasmsAntibodies Monoclonal HumanizedAsymptomaticDisease-Free Survivalchemistry.chemical_compoundBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansDoxorubicinNeoplasm Metastasisskin and connective tissue diseasesAgedEjection fractionbusiness.industryAntibodies MonoclonalGenes erbB-2Middle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerUp-RegulationSurgeryOncologyPaclitaxelchemistryDoxorubicinHeart failureFemalemedicine.symptombusinessmedicine.drug
researchProduct

Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.

2002

<i>Objective:</i> This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). <i>Methods:</i> Heavily pretreated patients with MBC, aged 18–75 years with World Health Organization performance status of 0–2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m<sup>2</sup>) followed by a weekly fixed dose of gemcitabine, 800 mg/m<sup>2</sup>, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomat…

AdultCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.drug_classmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsDocetaxelWorld Health OrganizationAntimetaboliteGastroenterologyDeoxycytidineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAgedChemotherapyPerformance statusDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyDocetaxelLymphatic MetastasisToxicityFemaleTaxoidsbusinessmedicine.drugOncology
researchProduct

Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.

2009

BACKGROUND: Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is a relatively new disease. The aim of this study was to evaluate the prevalence of BP-ONJ in breast cancer patients with osseous metastasis and bisphosphonate therapy. METHODS: A retrospective study was conducted in a EUSOMA accredited breast unit in Germany. All patients treated from January of 2000 to March of 2006 with metastatic breast cancer and bisphosphonate therapy were reviewed. All patients were contacted, and missing data were completed through structured interviews with their dentists and physicians (n = 75). Primary outcome was the development of BP-ONJ and the detection of possible additional trigger fa…

AdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentOral Surgical ProceduresBone NeoplasmsBreast NeoplasmsBreast cancerInternal medicineMedicineHumansAgedRetrospective StudiesAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)IncidenceOsteonecrosisBone metastasisCancerRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurgeryOncologyBreast diseasebusinessJaw DiseasesCancer
researchProduct

Combining tDCS with prismatic adaptation for non-invasive neuromodulation of the motor cortex

2017

Abstract Background Prismatic adaptation (PA) shifts visual field laterally and induces lateralized deviations of spatial attention. Recently, it has been suggested that prismatic goggles are also able to modulate brain excitability, with cognitive after-effects documented even in tasks not necessarily spatial in nature. Objective The aim of the present study was to test whether neuromodulatory effects obtained from tDCS and prismatic goggles could interact and induce homeostatic changes in corticospinal excitability. Methods Thirty-four subjects were submitted to single-pulse transcranial magnetic stimulation (TMS) over the right primary motor cortex to measure Input-Output (IO) curve as a…

AdultCognitive Neurosciencemedicine.medical_treatmentExperimental and Cognitive PsychologyElectromyographyTranscranial Direct Current Stimulation050105 experimental psychology03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineNeuromodulationHomeostatic plasticityAdaptation PsychologicalMetaplasticityNeuroplasticitytDCS TMS prismatic adaptation motor cortexmedicineHumans0501 psychology and cognitive sciencesMuscle SkeletalLensesAnalysis of VarianceNeuronal PlasticitySettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaTranscranial direct-current stimulationmedicine.diagnostic_testElectromyography05 social sciencesMotor CortexEvoked Potentials MotorAdaptation PhysiologicalTranscranial magnetic stimulationmedicine.anatomical_structureVisual PerceptionPsychologyNeurosciencePsychomotor Performance030217 neurology & neurosurgeryMotor cortexNeuropsychologia
researchProduct

Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: A contemporary series of 1800 interventions

2002

Abstract Objectives Contemporary series of open prostatectomies from Western countries are rare. Frequently, the analysis of the outcome of open prostatectomy refers to old experiences or to series from developing countries. Any comparison with transurethral resection of the prostate can be invalidated by complications of open surgery because of the lack of an adequate healthcare system and technology. Methods The Sicilian-Calabrian Society of Urology performed a retrospective study to assess the surgical management of benign prostatic hyperplasia in Sicily and Calabria in 1997 and 1998. A three-page questionnaire was sent to the 36 urologic units of these two Italian regions with more than…

AdultCross-Cultural ComparisonMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrinary systemProstatic HyperplasiaPostoperative ComplicationsProstatemedicineHumansSicilyTransurethral resection of the prostateAgedRetrospective StudiesAged 80 and overProstatectomybusiness.industryProstatectomyTransurethral Resection of ProstateRetrospective cohort studyMiddle AgedUnited StatesSurgerymedicine.anatomical_structureTreatment OutcomeItalyConcomitantHealth Care SurveysComplicationbusinessOpen Prostatectomy
researchProduct

Intra‐ and interreader reproducibility of PI‐RADSv2: A multireader study

2018

Background The Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) has been in use since 2015; while interreader reproducibility has been studied, there has been a paucity of studies investigating the intrareader reproducibility of PI-RADSv2. Purpose To evaluate both intra- and interreader reproducibility of PI-RADSv2 in the assessment of intraprostatic lesions using multiparametric magnetic resonance imaging (mpMRI). Study type Retrospective. Population/subjects In all, 102 consecutive biopsy-naive patients who underwent prostate MRI and subsequent MR/transrectal ultrasonography (MR/TRUS)-guided biopsy. Field strength/sequences Prostate mpMRI at 3T using endorectal with phased…

AdultImage-Guided BiopsyMaleIntraclass correlationBiopsyPopulationContrast MediaArticle030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineHumansMedicineRadiology Nuclear Medicine and imagingMultiparametric Magnetic Resonance ImagingStage (cooking)educationMultiparametric Magnetic Resonance ImagingAgedRetrospective StudiesUltrasonographyAged 80 and overObserver VariationReproducibilityeducation.field_of_studymedicine.diagnostic_testbusiness.industryProstateProstatic NeoplasmsReproducibility of ResultsMiddle AgedProstate-Specific AntigenReference StandardsMagnetic Resonance ImagingPI-RADSDiffusion Magnetic Resonance ImagingTransrectal ultrasonographybusinessNuclear medicineAlgorithmsKappaJournal of Magnetic Resonance Imaging
researchProduct

Different expression of thymidylate synthase in primary tumour and metastatic nodes in breast cancer patients.

2007

BACKGROUND: To date an accurate evaluation of predictive markers in breast cancer is mainly conducted at the primary site, although the main goal of the adjuvant therapy is the control of micrometastases. Adjuvant therapy drugs need a high proliferative cell rate to be effective. The proliferating activity can be evaluated by the Ki-67 marker and even by thymidylate synthase (TS), a cell cycle enzyme present in proliferating cells. In this study the TS levels in primary tumours were compared to those of their metastases. PATIENTS AND METHODS: The TS expression and Ki-67 were evaluated by means of immunohistochemistry in 80 primary breast tumours (PTs) and in their matched axillary metastati…

AdultKi-67 AntigenLymphatic MetastasisHumansBreast cancer thymidylate synthase Mib-1/Ki-67 metastatic lymph nodes.Breast NeoplasmsFemaleCell Growth ProcessesThymidylate SynthaseSettore MED/08 - Anatomia PatologicaImmunohistochemistryNeoplasm StagingAnticancer research
researchProduct

Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection.

2010

Assessment of liver fibrosis is crucial in HIV/HCV coinfected patients, in whom metabolic disturbances are frequent. Aims of this study were to analyse the association of two non-invasive liver fibrosis evaluation methods, liver stiffness measurement and FIB4, and their correlation with metabolic parameters.This was a single centre cross-sectional study. All patients underwent biochemical and virological assessment, FIB4 score, HOMA and transient elastography.Seventy-five patients were evaluated. Liver stiffness values positively correlated with FIB4 (R = 0.62; p0.0001). By ROC curve analysis the optimal cut-off for liver stiffness to identify high FIB4 was calculated as 10.1 kPa. The area …

AdultLiver CirrhosisMalemedicine.medical_specialtyHepatitis C virusHIV InfectionsHepacivirusmedicine.disease_causeGastroenterologyFibrosisInterquartile rangeInternal medicinemedicineHumansRetrospective StudiesHepatologybusiness.industryFibroTestGastroenterologyHIVHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyElasticityCross-Sectional StudiesLiverROC CurveHomeostatic model assessmentCoinfectionRNA ViralFemaleMetabolic syndromeTransient elastographybusinessFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of…

2020

BackgroundImmune checkpoint inhibition (ICI) is an essential treatment option in melanoma. Its outcome may be improved by a preceding radiation of metastases. This study aimed to investigate the impact of a preceding radiotherapy on the clinical outcome of ICI treatment.MethodsThis multicenter retrospective cohort study included patients who received anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or anti-programmed cell death protein 1 (PD-1) ICI with or without preceding radiotherapy for unresectable metastatic melanoma. ICI therapy outcome was measured as best overall response (BOR), progression-free (PFS) and overall survival (OS). Response and survival analyses were adjusted …

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtySkin NeoplasmsMetastatic melanoma2435medicine.medical_treatmentProgrammed Cell Death 1 ReceptorImmunologyMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyCTLA-4 Antigen1506Immune Checkpoint InhibitorsMelanomaradiotherapyRC254-282Survival analysisRetrospective StudiesClinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryMelanomaConfoundingNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyChemoradiotherapyMiddle Agedmedicine.diseaseProgression-Free SurvivalImmune checkpointRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMolecular MedicineFemalebusinessJournal for ImmunoTherapy of Cancer
researchProduct

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

2019

Abstract Background This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods 148 mRCC patients were evaluated. According to Heng score 15.5%, 60.1% and 24.4% of patients were at poor risk, intermediate and favorable risk, respectively. Results PFS, OS, DCR and ORR were 7.14 months, 15.5 months, 70.6% and 16.6%, respectively. The duration of prior sunitinib treatment correlated with a longer significant mPFS, 8.8 vs 6.3 months, respectively. Axitinib therapy was safe, without grade 4 adverse events. The most frequent toxicities of all grades were: fati…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAxitinibAxitinib; Metastatic; Renal cancer; Sunitinib; Treatmentmedicine.medical_treatmentPopulationlcsh:MedicineKaplan-Meier EstimateDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicineSunitinibHumansMedicineNeoplasm MetastasiseducationAdverse effectMetastatic renal cell cancerCarcinoma Renal CellAgedAged 80 and overSecond-line therapyeducation.field_of_studybusiness.industrySunitinibResearchlcsh:RGeneral MedicineMiddle AgedKidney NeoplasmsNephrectomyAxitinibTreatment030104 developmental biologyRenal cancer030220 oncology & carcinogenesisMultivariate AnalysisMetastaticFemalebusinessmedicine.drugJournal of Translational Medicine
researchProduct